Starling Biosciences is pioneering the first integrated GPER-targeting platform, advancing both GPER degraders for oncology and GPER agonists for cardiometabolic and vascular disease. GPER is a validated but previously inaccessible estrogen-signaling receptor highly expressed in solid tumors and key metabolic tissues.

Starling has consolidated foundational IP and the discovery engines from the pioneering academic labs in GPER biology, creating a differentiated enablement platform with optimized ligands, assays, models, and degrader chemistry.

Lead programs include a first-in-class GPER degrader for TNBC and next-generation agonists addressing metabolic dysfunction and vascular health.